FDA Approves Brepocitinib for Adult Dermatomyositis Treatment

The U.S. Food and Drug Administration has approved brepocitinib, marketed as LISRAYA, for the treatment of adult patients with dermatomyositis. Roivant Sciences announced the approval, making the medication commercially available across the United States.